<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00793403</url>
  </required_header>
  <id_info>
    <org_study_id>0881A1-102317</org_study_id>
    <secondary_id>0881A-102317 ; B1801118</secondary_id>
    <nct_id>NCT00793403</nct_id>
  </id_info>
  <brief_title>Current Adoption of Composite Indices in Evaluating Rheumatoid Arthritis Patients: An Observational Study</brief_title>
  <acronym>New Indices</acronym>
  <official_title>Current Adoption Of Composite Indices In Evaluating Rheumatoid Arthritis Patients: An Observational Study (&quot;NEW INDICES Study&quot;)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an observational study of composite indices, including the CLARA (CLinical ARthritis
      Activity) index, in rheumatoid arthritis (RA) patients in routine clinical practice in Italy
      in order to evaluate clinical remission and low disease activity. Data will be collected only
      from patients providing informed consent. In this study we aimed to assess the psychometric
      properties of a new composite instrument termed CLinical ARthritis Activity (PRO-CLARA) that
      uses only three PRO measures from among the 7 ACR Core Data Set. We hypothesized that this
      index would facilitate rapid and easy RA activity assessment in daily routine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients who respond to inclusion/exclusion criteria at baseline will be considered
      valuable for the analysis.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Remission as Per Modified American College of Rheumatology (Modified ACR) Criteria at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Modified ACR: participant considered in RA remission if at any time point 1) participant satisfied all of the following criteria: tender joint count(TJC) less than or equal to(&lt;=)1;swollen joint count(SJC)&lt;=1 (TJC, SJC based on 28-joints);C-reactive protein(CRP)&lt;=1 milligram/deciliter(mg/dL); patient global assessment (PtGA) &lt;=1 (assessed on 0-10 centimeter[cm] visual analog scale[VAS]) or 2) participant had Simplified Disease Activity Index score of &lt;=3.3 (SDAI, numerical sum of 5 outcome parameters: TJC, SJC, PtGA, physician global assessment [PGA, assessed on 0-10 cm VAS], and CRP [mg/dL]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Remission as Per Modified American College of Rheumatology (Modified ACR) Criteria at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Modified ACR: participant was considered in RA remission if at any time point 1) participant satisfied all of the following criteria: TJC &lt;=1; SJC &lt;=1 (TJC, SJC based on 28-joints); CRP &lt;=1 mg/dL; PtGA&lt;=1 (assessed on 0-10 centimeter[cm] visual analog scale[VAS]) or 2) participant had SDAI score of &lt;=3.3 (SDAI: the numerical sum of 5 outcome parameters: TJC, SJC, PtGA, PGA [assessed on 0-10 cm VAS], and CRP [mg/dL]).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Disease Activity: Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>OMERACT minimal disease activity: participant considered with minimal disease activity if he/she met 5 of 7 criteria: Pain &lt;=2 (assessed on a 0-10 cm VAS, 0 cm=no pain and 10 cm=worst possible pain); SJC &lt;=1; TJC &lt;=1 (SJC, TJC based on 28-joints); Health Assessment Questionnaire (HAQ) &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); PGA &lt;=1.5; PtGA &lt;=2 (PGA, PtGA: assessed on 0-10 cm VAS, higher score = greater affection due to disease activity); erythrocyte sedimentation rate (ESR) &lt;=20 millimeter per hour (mm/hr).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Disease Activity: Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>OMERACT minimal disease activity: participant considered with minimal disease activity if he/she met 5 of 7 criteria: Pain &lt;=2 (assessed on a 0-10 cm VAS, 0 cm=no pain and 10 cm=worst possible pain); SJC &lt;=1; TJC &lt;=1 (SJC, TJC based on 28-joints); HAQ &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); PGA &lt;=1.5; PtGA &lt;=2 (PGA, PtGA: assessed on 0-10 cm VAS, higher score = greater affection due to disease activity); ESR &lt;=20 mm/hr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Disease Activity: Italian Group for the Study of Early Arthritis (GISEA) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>GISEA minimal disease activity criteria: a participant was considered with minimal disease activity if he/she met the following criteria: SJC &lt;=2 (based on 28-joints); HAQ &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); and ESR &lt;=20 mm/hr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimal Disease Activity: Italian Group for the Study of Early Arthritis (GISEA) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>GISEA minimal disease activity criteria: a participant was considered with minimal disease activity if he/she met the following criteria: SJC &lt;=2 (based on 28-joints); HAQ &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); and ESR &lt;=20 mm/hr.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Swollen Joints (SJC) and Tender Joints (TJC) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Swollen Joints (SJC) and Tender Joints (TJC) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Activity Score Based on 28-joints Count (DAS28) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>DAS28 calculated from SJC and TJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10 cm VAS; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 &lt;= 3.2 implied low disease activity and &gt; 3.2 to 5.1 implied moderate to high disease activity, and DAS28 &lt; 2.6 = remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Activity Score Based on 28-joints Count (DAS28) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>DAS28 calculated from SJC and TJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10 cm VAS; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 &lt;= 3.2 implied low disease activity and &gt; 3.2 to 5.1 implied moderate to high disease activity, and DAS28 &lt; 2.6 = remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Simplified Disease Activity Index (SDAI) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity), and CRP (mg/dL). SDAI total score= 0-86. SDAI &lt;=3.3 indicates disease remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Simplified Disease Activity Index (SDAI) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity), and CRP (mg/dL). SDAI total score= 0-86. SDAI &lt;=3.3 indicates disease remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rheumatoid Arthritis Disease Activity Index (RADAI) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>RADAI:self-assessed measure of disease activity in RA. Consists of 5 items: global disease activity(GDA) in past 6 months; current disease activity(CDA) as measured by SJC and TJC; current arthritis pain; current duration of morning stiffness; current TJC. GDA,CDA and pain were scored on an 11-point numerical rating scale,0=no disease activity/pain to 10=extreme disease activity/pain. Current morning stiffness and TJC were transformed to a 0-10 point scale,higher scores=more disease activity. RADAI total score=sum of individual items divided by 5;range 0-10, higher score=more disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rheumatoid Arthritis Disease Activity Index (RADAI) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>RADAI:self-assessed measure of disease activity in RA. Consists of 5 items: GDA in past 6 months; CDA as measured by SJC and TJC; current arthritis pain; current duration of morning stiffness; current TJC. GDA,CDA and pain were scored on an 11-point numerical rating scale,0=no disease activity/pain to 10=extreme disease activity/pain. Current morning stiffness and TJC were transformed to a 0-10 point scale,higher scores=more disease activity. RADAI total score=sum of individual items divided by 5;range 0-10, higher score=more disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Disease Activity Index (CDAI) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score = 0-76. CDAI &lt;= 2.8 indicates disease remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Disease Activity Index (CDAI) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score = 0-76. CDAI &lt;= 2.8 indicates disease remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcomes - Clinical Arthritis Activity (PRO-CLARA ) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>PRO-CLARA:self-administered index of RA activity. Consists of 3-items: participant's physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC(based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); PtGA (participant rated disease activity on 0-10 cm VAS, 0=very well, 10 cm=very poorly). Participant's physical function and TJC were transformed on a 0-10 point scale, higher scores=more disease activity. PRO-CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Reported Outcomes - Clinical Arthritis Activity (PRO-CLARA ) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>PRO-CLARA:self-administered index of RA activity. Consists of 3-items: participant's physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC(based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); PtGA (participant rated disease activity on 0-10 cm VAS, 0=very well, 10 cm=very poorly). Participant's physical function and TJC were transformed on a 0-10 point scale, higher scores=more disease activity. PRO-CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Arthritis Activity (CLARA) Index at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>CLARA: index of RA activity. Consists of 3-items: participant's physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC (based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); SJC (based on 28-joints). Each item was transformed on a 0-10 point scale, higher scores=more disease activity. CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Arthritis Activity (CLARA) Index at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>CLARA: index of RA activity. Consists of 3-items: participant's physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC (based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); SJC (based on 28-joints). Each item was transformed on a 0-10 point scale, higher scores=more disease activity. CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Global Assessment (PtGA) of Disease Activity at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poorly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Global Assessment (PtGA) of Disease Activity at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poorly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician Global Assessment (PGA) of Disease Activity at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Physician Global Assessment of Arthritis was measured on a 0 to 10 cm VAS, where 0 cm = very good and 10 cm = very bad.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Physician Global Assessment (PGA) of Disease Activity at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Physician Global Assessment of Arthritis was measured on a 0 to 10 cm VAS, where 0 cm = very good and 10 cm = very bad.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Fatigue Scale (VAFS) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Participants assessed their fatigue using a 0 - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Analog Fatigue Scale (VAFS) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Participants assessed their fatigue using a 0 - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive Protein (CRP) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is &lt;1 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-reactive Protein (CRP) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is &lt;1 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythrocyte Sedimentation Rate (ESR) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Erythrocyte Sedimentation Rate (ESR) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Rheumatoid Factor (RF) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 units per milliliter (U/mL) is considered positive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Rheumatoid Factor (RF) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 U/mL is considered positive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's General Health Assessment at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Participants answered: &quot;How would you describe your general health today?&quot; Participants assessed their general health using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient's General Health Assessment at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Participants answered: &quot;How would you describe your general health today?&quot; Participants assessed their general health using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poor.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Assessment of Arthritis Pain at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Participants rated the severity of arthritis pain on a 0 to 10 cm VAS, where 0 cm = no pain and 10 cm = most severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient Assessment of Arthritis Pain at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Participants rated the severity of arthritis pain on a 0 to 10 cm VAS, where 0 cm = no pain and 10 cm = most severe pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Morning Stiffness at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. Increase in stiffness duration from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Duration of Morning Stiffness at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. Increase in stiffness duration from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Assessment Questionnaire (HAQ) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>HAQ: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health Assessment Questionnaire (HAQ) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>HAQ: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recent-Onset Arthritis Disability (ROAD) at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>ROAD questionnaire: valid and responsive tool for measuring functional ability in RA participants. Consists of 12-items related to fine movements of upper extremity, locomotor activities of lower extremity, and activities that involve both upper and lower extremities. For each item participant rated the level of difficulty over the past week on a 5-point scale ranging from 0 (without any difficulty) to 4 (unable to do). Total ROAD score were transformed to a 0 to 10 point scale, where 0 = best status and 10 = poorest status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recent-Onset Arthritis Disability (ROAD) at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>ROAD questionnaire: valid and responsive tool for measuring functional ability in RA participants. Consists of 12-items related to fine movements of upper extremity, locomotor activities of lower extremity, and activities that involve both upper and lower extremities. For each item participant rated the level of difficulty over the past week on a 5-point scale ranging from 0 (without any difficulty) to 4 (unable to do). Total ROAD score were transformed to a 0 to 10 point scale, where 0 = best status and 10 = poorest status.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological Assessment of Hands and Feet Based on Sharp-van Der Hejde (SvH) Scoring Method at Month 6</measure>
    <time_frame>Month 6</time_frame>
    <description>SvH method included 16 areas for erosions and 15 areas for joint space narrowing (JSN) and subluxation/luxation in each hand, 6 areas for erosions and 6 areas for JSN and subluxation/luxation in each foot. Erosion per joint scored on 0-5 point scale; 0=normal joint to 5=complete collapse. Total erosion score for hands:0-160, for feet:0-120. JSN and subluxation/luxation scored on 0-4 point scale; 0=normal joint to 4= a bony ankylosis/a complete luxation of joint. Total JSN and subluxation/luxation score for hands:0-120, for feet:0-48. Total SvH score = 0-448; higher score=more erosion and JSN.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Radiological Assessment of Hands and Feet Based on Sharp-Van Der Hejde (SvH) Scoring Method at Month 12</measure>
    <time_frame>Month 12</time_frame>
    <description>SvH method included 16 areas for erosions and 15 areas for JSN and subluxation/luxation in each hand, 6 areas for erosions and 6 areas for JSN and subluxation/luxation in each foot. Erosion per joint scored on 0-5 point scale; 0=normal joint to 5=complete collapse. Total erosion score for hands:0-160, for feet:0-120. JSN and subluxation/luxation scored on 0-4 point scale; 0=normal joint to 4= a bony ankylosis/a complete luxation of joint. Total JSN and subluxation/luxation score for hands:0-120, for feet:0-48. Total SvH score = 0-448; higher score=more erosion and JSN.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">293</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <description>As per routine clinical care</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>As per routinary clinical care</intervention_name>
    <description>As per routine clinical care</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Observational study</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eighteen years of age or older with diagnosis of RA based on the 1987 American College
             of Rheumatology (ACR) criteria and in accordance with local guidelines.

          -  Patients eligible to anti-TNF therapy

          -  Patients na√Øve to anti-TNFa drugs

          -  Patients with radiography (hands and feet) executed by 6 months before the baseline or
             at baseline according to modified Sharp Van der Hejde method [Sharp JT et al. 1985;
             Sharp JT. Et al. 1989; Van der Heijde DM et al. 1989] Patients capable of
             understanding and completing the questionnaire Patients capable of understanding and
             signing an informed consent form

        Exclusion Criteria:

          -  Patients with tumors

          -  Patients already included in clinical trials
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=0881A1-102317&amp;StudyName=Current%20adoption%20of%20composite%20indices%20in%20evaluating%20rheumatoid%20arthritis%20patients%3A%20An%20Observational%20Study</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2008</study_first_submitted>
  <study_first_submitted_qc>November 18, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2008</study_first_posted>
  <results_first_submitted>December 31, 2012</results_first_submitted>
  <results_first_submitted_qc>December 31, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 4, 2013</results_first_posted>
  <last_update_submitted>December 31, 2012</last_update_submitted>
  <last_update_submitted_qc>December 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Observational cohort</keyword>
  <keyword>prospectives</keyword>
  <keyword>multicentre</keyword>
  <keyword>the Italian study RA patient CLARA and PRO-CLARA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Participants</title>
          <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="293"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="220"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Participants</title>
          <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="220"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.65" spread="12.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Remission as Per Modified American College of Rheumatology (Modified ACR) Criteria at Month 6</title>
        <description>Modified ACR: participant considered in RA remission if at any time point 1) participant satisfied all of the following criteria: tender joint count(TJC) less than or equal to(&lt;=)1;swollen joint count(SJC)&lt;=1 (TJC, SJC based on 28-joints);C-reactive protein(CRP)&lt;=1 milligram/deciliter(mg/dL); patient global assessment (PtGA) &lt;=1 (assessed on 0-10 centimeter[cm] visual analog scale[VAS]) or 2) participant had Simplified Disease Activity Index score of &lt;=3.3 (SDAI, numerical sum of 5 outcome parameters: TJC, SJC, PtGA, physician global assessment [PGA, assessed on 0-10 cm VAS], and CRP [mg/dL]).</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Remission as Per Modified American College of Rheumatology (Modified ACR) Criteria at Month 6</title>
          <description>Modified ACR: participant considered in RA remission if at any time point 1) participant satisfied all of the following criteria: tender joint count(TJC) less than or equal to(&lt;=)1;swollen joint count(SJC)&lt;=1 (TJC, SJC based on 28-joints);C-reactive protein(CRP)&lt;=1 milligram/deciliter(mg/dL); patient global assessment (PtGA) &lt;=1 (assessed on 0-10 centimeter[cm] visual analog scale[VAS]) or 2) participant had Simplified Disease Activity Index score of &lt;=3.3 (SDAI, numerical sum of 5 outcome parameters: TJC, SJC, PtGA, physician global assessment [PGA, assessed on 0-10 cm VAS], and CRP [mg/dL]).</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Remission as Per Modified American College of Rheumatology (Modified ACR) Criteria at Month 12</title>
        <description>Modified ACR: participant was considered in RA remission if at any time point 1) participant satisfied all of the following criteria: TJC &lt;=1; SJC &lt;=1 (TJC, SJC based on 28-joints); CRP &lt;=1 mg/dL; PtGA&lt;=1 (assessed on 0-10 centimeter[cm] visual analog scale[VAS]) or 2) participant had SDAI score of &lt;=3.3 (SDAI: the numerical sum of 5 outcome parameters: TJC, SJC, PtGA, PGA [assessed on 0-10 cm VAS], and CRP [mg/dL]).</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Remission as Per Modified American College of Rheumatology (Modified ACR) Criteria at Month 12</title>
          <description>Modified ACR: participant was considered in RA remission if at any time point 1) participant satisfied all of the following criteria: TJC &lt;=1; SJC &lt;=1 (TJC, SJC based on 28-joints); CRP &lt;=1 mg/dL; PtGA&lt;=1 (assessed on 0-10 centimeter[cm] visual analog scale[VAS]) or 2) participant had SDAI score of &lt;=3.3 (SDAI: the numerical sum of 5 outcome parameters: TJC, SJC, PtGA, PGA [assessed on 0-10 cm VAS], and CRP [mg/dL]).</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimal Disease Activity: Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT) at Month 6</title>
        <description>OMERACT minimal disease activity: participant considered with minimal disease activity if he/she met 5 of 7 criteria: Pain &lt;=2 (assessed on a 0-10 cm VAS, 0 cm=no pain and 10 cm=worst possible pain); SJC &lt;=1; TJC &lt;=1 (SJC, TJC based on 28-joints); Health Assessment Questionnaire (HAQ) &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); PGA &lt;=1.5; PtGA &lt;=2 (PGA, PtGA: assessed on 0-10 cm VAS, higher score = greater affection due to disease activity); erythrocyte sedimentation rate (ESR) &lt;=20 millimeter per hour (mm/hr).</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Disease Activity: Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT) at Month 6</title>
          <description>OMERACT minimal disease activity: participant considered with minimal disease activity if he/she met 5 of 7 criteria: Pain &lt;=2 (assessed on a 0-10 cm VAS, 0 cm=no pain and 10 cm=worst possible pain); SJC &lt;=1; TJC &lt;=1 (SJC, TJC based on 28-joints); Health Assessment Questionnaire (HAQ) &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); PGA &lt;=1.5; PtGA &lt;=2 (PGA, PtGA: assessed on 0-10 cm VAS, higher score = greater affection due to disease activity); erythrocyte sedimentation rate (ESR) &lt;=20 millimeter per hour (mm/hr).</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimal Disease Activity: Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT) at Month 12</title>
        <description>OMERACT minimal disease activity: participant considered with minimal disease activity if he/she met 5 of 7 criteria: Pain &lt;=2 (assessed on a 0-10 cm VAS, 0 cm=no pain and 10 cm=worst possible pain); SJC &lt;=1; TJC &lt;=1 (SJC, TJC based on 28-joints); HAQ &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); PGA &lt;=1.5; PtGA &lt;=2 (PGA, PtGA: assessed on 0-10 cm VAS, higher score = greater affection due to disease activity); ESR &lt;=20 mm/hr.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Disease Activity: Outcome Measures in Rheumatology Arthritis Clinical Trials (OMERACT) at Month 12</title>
          <description>OMERACT minimal disease activity: participant considered with minimal disease activity if he/she met 5 of 7 criteria: Pain &lt;=2 (assessed on a 0-10 cm VAS, 0 cm=no pain and 10 cm=worst possible pain); SJC &lt;=1; TJC &lt;=1 (SJC, TJC based on 28-joints); HAQ &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); PGA &lt;=1.5; PtGA &lt;=2 (PGA, PtGA: assessed on 0-10 cm VAS, higher score = greater affection due to disease activity); ESR &lt;=20 mm/hr.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimal Disease Activity: Italian Group for the Study of Early Arthritis (GISEA) at Month 6</title>
        <description>GISEA minimal disease activity criteria: a participant was considered with minimal disease activity if he/she met the following criteria: SJC &lt;=2 (based on 28-joints); HAQ &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); and ESR &lt;=20 mm/hr.</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Disease Activity: Italian Group for the Study of Early Arthritis (GISEA) at Month 6</title>
          <description>GISEA minimal disease activity criteria: a participant was considered with minimal disease activity if he/she met the following criteria: SJC &lt;=2 (based on 28-joints); HAQ &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); and ESR &lt;=20 mm/hr.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Minimal Disease Activity: Italian Group for the Study of Early Arthritis (GISEA) at Month 12</title>
        <description>GISEA minimal disease activity criteria: a participant was considered with minimal disease activity if he/she met the following criteria: SJC &lt;=2 (based on 28-joints); HAQ &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); and ESR &lt;=20 mm/hr.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Minimal Disease Activity: Italian Group for the Study of Early Arthritis (GISEA) at Month 12</title>
          <description>GISEA minimal disease activity criteria: a participant was considered with minimal disease activity if he/she met the following criteria: SJC &lt;=2 (based on 28-joints); HAQ &lt;=0.5 (assessment of ability to perform task on 0-3 point scale, 0=least difficulty and 3=extreme difficulty); and ESR &lt;=20 mm/hr.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Swollen Joints (SJC) and Tender Joints (TJC) at Month 6</title>
        <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Swollen Joints (SJC) and Tender Joints (TJC) at Month 6</title>
          <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SJC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.80" spread="3.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TJC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.62" spread="5.01"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Swollen Joints (SJC) and Tender Joints (TJC) at Month 12</title>
        <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
        <time_frame>Month 12</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Swollen Joints (SJC) and Tender Joints (TJC) at Month 12</title>
          <description>Number of swollen joints was determined by examination of 28 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.
Number of tender joints was determined by examining 28 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>Joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="155"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SJC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="2.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TJC</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" spread="3.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Activity Score Based on 28-joints Count (DAS28) at Month 6</title>
        <description>DAS28 calculated from SJC and TJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10 cm VAS; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 &lt;= 3.2 implied low disease activity and &gt; 3.2 to 5.1 implied moderate to high disease activity, and DAS28 &lt; 2.6 = remission.</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Based on 28-joints Count (DAS28) at Month 6</title>
          <description>DAS28 calculated from SJC and TJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10 cm VAS; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 &lt;= 3.2 implied low disease activity and &gt; 3.2 to 5.1 implied moderate to high disease activity, and DAS28 &lt; 2.6 = remission.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Disease Activity Score Based on 28-joints Count (DAS28) at Month 12</title>
        <description>DAS28 calculated from SJC and TJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10 cm VAS; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 &lt;= 3.2 implied low disease activity and &gt; 3.2 to 5.1 implied moderate to high disease activity, and DAS28 &lt; 2.6 = remission.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Based on 28-joints Count (DAS28) at Month 12</title>
          <description>DAS28 calculated from SJC and TJC using the 28 joints count, the ESR (mm/hr) and PtGA of disease activity (participant rated arthritis activity assessment with transformed scores ranging 0 to 10 cm VAS; higher scores indicated greater affectation due to disease activity). Total score range: 0 to 9.4, higher score indicated more disease activity. DAS28 &lt;= 3.2 implied low disease activity and &gt; 3.2 to 5.1 implied moderate to high disease activity, and DAS28 &lt; 2.6 = remission.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Simplified Disease Activity Index (SDAI) at Month 6</title>
        <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity), and CRP (mg/dL). SDAI total score= 0-86. SDAI &lt;=3.3 indicates disease remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high disease activity.</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Simplified Disease Activity Index (SDAI) at Month 6</title>
          <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity), and CRP (mg/dL). SDAI total score= 0-86. SDAI &lt;=3.3 indicates disease remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high disease activity.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Simplified Disease Activity Index (SDAI) at Month 12</title>
        <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity), and CRP (mg/dL). SDAI total score= 0-86. SDAI &lt;=3.3 indicates disease remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high disease activity.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Simplified Disease Activity Index (SDAI) at Month 12</title>
          <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity), and CRP (mg/dL). SDAI total score= 0-86. SDAI &lt;=3.3 indicates disease remission, &gt;3.4 to 11 = low disease activity, &gt;11 to 26 = moderate disease activity, and &gt;26 = high disease activity.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rheumatoid Arthritis Disease Activity Index (RADAI) at Month 6</title>
        <description>RADAI:self-assessed measure of disease activity in RA. Consists of 5 items: global disease activity(GDA) in past 6 months; current disease activity(CDA) as measured by SJC and TJC; current arthritis pain; current duration of morning stiffness; current TJC. GDA,CDA and pain were scored on an 11-point numerical rating scale,0=no disease activity/pain to 10=extreme disease activity/pain. Current morning stiffness and TJC were transformed to a 0-10 point scale,higher scores=more disease activity. RADAI total score=sum of individual items divided by 5;range 0-10, higher score=more disease activity.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Rheumatoid Arthritis Disease Activity Index (RADAI) at Month 6</title>
          <description>RADAI:self-assessed measure of disease activity in RA. Consists of 5 items: global disease activity(GDA) in past 6 months; current disease activity(CDA) as measured by SJC and TJC; current arthritis pain; current duration of morning stiffness; current TJC. GDA,CDA and pain were scored on an 11-point numerical rating scale,0=no disease activity/pain to 10=extreme disease activity/pain. Current morning stiffness and TJC were transformed to a 0-10 point scale,higher scores=more disease activity. RADAI total score=sum of individual items divided by 5;range 0-10, higher score=more disease activity.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.26" spread="1.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Rheumatoid Arthritis Disease Activity Index (RADAI) at Month 12</title>
        <description>RADAI:self-assessed measure of disease activity in RA. Consists of 5 items: GDA in past 6 months; CDA as measured by SJC and TJC; current arthritis pain; current duration of morning stiffness; current TJC. GDA,CDA and pain were scored on an 11-point numerical rating scale,0=no disease activity/pain to 10=extreme disease activity/pain. Current morning stiffness and TJC were transformed to a 0-10 point scale,higher scores=more disease activity. RADAI total score=sum of individual items divided by 5;range 0-10, higher score=more disease activity.</description>
        <time_frame>Month 12</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Rheumatoid Arthritis Disease Activity Index (RADAI) at Month 12</title>
          <description>RADAI:self-assessed measure of disease activity in RA. Consists of 5 items: GDA in past 6 months; CDA as measured by SJC and TJC; current arthritis pain; current duration of morning stiffness; current TJC. GDA,CDA and pain were scored on an 11-point numerical rating scale,0=no disease activity/pain to 10=extreme disease activity/pain. Current morning stiffness and TJC were transformed to a 0-10 point scale,higher scores=more disease activity. RADAI total score=sum of individual items divided by 5;range 0-10, higher score=more disease activity.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Disease Activity Index (CDAI) at Month 6</title>
        <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score = 0-76. CDAI &lt;= 2.8 indicates disease remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high disease activity.</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Disease Activity Index (CDAI) at Month 6</title>
          <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score = 0-76. CDAI &lt;= 2.8 indicates disease remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high disease activity.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Disease Activity Index (CDAI) at Month 12</title>
        <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score = 0-76. CDAI &lt;= 2.8 indicates disease remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high disease activity.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Disease Activity Index (CDAI) at Month 12</title>
          <description>The CDAI is the numerical sum of 4 outcome parameters: TJC and SJC (based on a 28-joint assessment), PtGA and PGA (assessed on 0-10 cm VAS; higher scores=greater affection due to disease activity). CDAI total score = 0-76. CDAI &lt;= 2.8 indicates disease remission, &gt;2.8 to 10 = low disease activity, &gt;10 to 22 = moderate disease activity, and &gt;22 = high disease activity.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Reported Outcomes - Clinical Arthritis Activity (PRO-CLARA ) at Month 6</title>
        <description>PRO-CLARA:self-administered index of RA activity. Consists of 3-items: participant‚Äôs physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC(based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); PtGA (participant rated disease activity on 0-10 cm VAS, 0=very well, 10 cm=very poorly). Participant‚Äôs physical function and TJC were transformed on a 0-10 point scale, higher scores=more disease activity. PRO-CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes - Clinical Arthritis Activity (PRO-CLARA ) at Month 6</title>
          <description>PRO-CLARA:self-administered index of RA activity. Consists of 3-items: participant‚Äôs physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC(based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); PtGA (participant rated disease activity on 0-10 cm VAS, 0=very well, 10 cm=very poorly). Participant‚Äôs physical function and TJC were transformed on a 0-10 point scale, higher scores=more disease activity. PRO-CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Reported Outcomes - Clinical Arthritis Activity (PRO-CLARA ) at Month 12</title>
        <description>PRO-CLARA:self-administered index of RA activity. Consists of 3-items: participant‚Äôs physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC(based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); PtGA (participant rated disease activity on 0-10 cm VAS, 0=very well, 10 cm=very poorly). Participant‚Äôs physical function and TJC were transformed on a 0-10 point scale, higher scores=more disease activity. PRO-CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Reported Outcomes - Clinical Arthritis Activity (PRO-CLARA ) at Month 12</title>
          <description>PRO-CLARA:self-administered index of RA activity. Consists of 3-items: participant‚Äôs physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC(based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); PtGA (participant rated disease activity on 0-10 cm VAS, 0=very well, 10 cm=very poorly). Participant‚Äôs physical function and TJC were transformed on a 0-10 point scale, higher scores=more disease activity. PRO-CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Arthritis Activity (CLARA) Index at Month 6</title>
        <description>CLARA: index of RA activity. Consists of 3-items: participant‚Äôs physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC (based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); SJC (based on 28-joints). Each item was transformed on a 0-10 point scale, higher scores=more disease activity. CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Arthritis Activity (CLARA) Index at Month 6</title>
          <description>CLARA: index of RA activity. Consists of 3-items: participant‚Äôs physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC (based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); SJC (based on 28-joints). Each item was transformed on a 0-10 point scale, higher scores=more disease activity. CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.79" spread="1.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Clinical Arthritis Activity (CLARA) Index at Month 12</title>
        <description>CLARA: index of RA activity. Consists of 3-items: participant‚Äôs physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC (based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); SJC (based on 28-joints). Each item was transformed on a 0-10 point scale, higher scores=more disease activity. CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
        <time_frame>Month 12</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Arthritis Activity (CLARA) Index at Month 12</title>
          <description>CLARA: index of RA activity. Consists of 3-items: participant‚Äôs physical function (12 questions each scored on a 0 [without any difficulty] to 4 [unable to do] point scale); TJC (based on 16-joints, tenderness assessed on 0 [none] to 3 [severe] point scale); SJC (based on 28-joints). Each item was transformed on a 0-10 point scale, higher scores=more disease activity. CLARA total score=sum of scores of all 3 items divided by 3, range= 0-10, higher scores=more disease activity.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="137"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.39" spread="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Global Assessment (PtGA) of Disease Activity at Month 6</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poorly.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment (PtGA) of Disease Activity at Month 6</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poorly.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.71" spread="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Global Assessment (PtGA) of Disease Activity at Month 12</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poorly.</description>
        <time_frame>Month 12</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment (PtGA) of Disease Activity at Month 12</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poorly.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.35" spread="2.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physician Global Assessment (PGA) of Disease Activity at Month 6</title>
        <description>Physician Global Assessment of Arthritis was measured on a 0 to 10 cm VAS, where 0 cm = very good and 10 cm = very bad.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment (PGA) of Disease Activity at Month 6</title>
          <description>Physician Global Assessment of Arthritis was measured on a 0 to 10 cm VAS, where 0 cm = very good and 10 cm = very bad.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.11" spread="2.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Physician Global Assessment (PGA) of Disease Activity at Month 12</title>
        <description>Physician Global Assessment of Arthritis was measured on a 0 to 10 cm VAS, where 0 cm = very good and 10 cm = very bad.</description>
        <time_frame>Month 12</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment (PGA) of Disease Activity at Month 12</title>
          <description>Physician Global Assessment of Arthritis was measured on a 0 to 10 cm VAS, where 0 cm = very good and 10 cm = very bad.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="147"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.60" spread="1.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Fatigue Scale (VAFS) at Month 6</title>
        <description>Participants assessed their fatigue using a 0 - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue.</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Fatigue Scale (VAFS) at Month 6</title>
          <description>Participants assessed their fatigue using a 0 - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Analog Fatigue Scale (VAFS) at Month 12</title>
        <description>Participants assessed their fatigue using a 0 - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analog Fatigue Scale (VAFS) at Month 12</title>
          <description>Participants assessed their fatigue using a 0 - 100 mm VAS, where 0 mm = no fatigue and 100 mm = worst possible fatigue.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C-reactive Protein (CRP) at Month 6</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is &lt;1 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (CRP) at Month 6</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is &lt;1 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.16" spread="4.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>C-reactive Protein (CRP) at Month 12</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is &lt;1 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
        <time_frame>Month 12</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>C-reactive Protein (CRP) at Month 12</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is &lt;1 mg/dL. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="136"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Erythrocyte Sedimentation Rate (ESR) at Month 6</title>
        <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Sedimentation Rate (ESR) at Month 6</title>
          <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="200"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.02" spread="19.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Erythrocyte Sedimentation Rate (ESR) at Month 12</title>
        <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.</description>
        <time_frame>Month 12</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Sedimentation Rate (ESR) at Month 12</title>
          <description>ESR is a laboratory test that provides a non-specific measure of inflammation. The test assesses the rate at which red blood cells fall in a test tube. Normal range is 0-30 mm/hr. A higher rate is consistent with inflammation.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>mm/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="152"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.92" spread="15.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Rheumatoid Factor (RF) at Month 6</title>
        <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 units per milliliter (U/mL) is considered positive.</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rheumatoid Factor (RF) at Month 6</title>
          <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 units per milliliter (U/mL) is considered positive.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Rheumatoid Factor (RF) at Month 12</title>
        <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 U/mL is considered positive.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Rheumatoid Factor (RF) at Month 12</title>
          <description>RF is the auto antibody directed against immunoglobulin G (IgG) and its concentration is observed in human serum or plasma. RF value higher than 20 U/mL is considered positive.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient‚Äôs General Health Assessment at Month 6</title>
        <description>Participants answered: &quot;How would you describe your general health today?&quot; Participants assessed their general health using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poor.</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient‚Äôs General Health Assessment at Month 6</title>
          <description>Participants answered: &quot;How would you describe your general health today?&quot; Participants assessed their general health using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poor.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient‚Äôs General Health Assessment at Month 12</title>
        <description>Participants answered: &quot;How would you describe your general health today?&quot; Participants assessed their general health using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poor.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient‚Äôs General Health Assessment at Month 12</title>
          <description>Participants answered: &quot;How would you describe your general health today?&quot; Participants assessed their general health using a 0 - 10 cm VAS, where 0 cm = very well and 10 cm = very poor.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Assessment of Arthritis Pain at Month 6</title>
        <description>Participants rated the severity of arthritis pain on a 0 to 10 cm VAS, where 0 cm = no pain and 10 cm = most severe pain.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Arthritis Pain at Month 6</title>
          <description>Participants rated the severity of arthritis pain on a 0 to 10 cm VAS, where 0 cm = no pain and 10 cm = most severe pain.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.58" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Patient Assessment of Arthritis Pain at Month 12</title>
        <description>Participants rated the severity of arthritis pain on a 0 to 10 cm VAS, where 0 cm = no pain and 10 cm = most severe pain.</description>
        <time_frame>Month 12</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Arthritis Pain at Month 12</title>
          <description>Participants rated the severity of arthritis pain on a 0 to 10 cm VAS, where 0 cm = no pain and 10 cm = most severe pain.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="2.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Morning Stiffness at Month 6</title>
        <description>Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. Increase in stiffness duration from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Morning Stiffness at Month 6</title>
          <description>Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. Increase in stiffness duration from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Duration of Morning Stiffness at Month 12</title>
        <description>Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. Increase in stiffness duration from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Morning Stiffness at Month 12</title>
          <description>Duration of morning stiffness: Time elapsed when participant woke up in morning and was able to resume normal activities without stiffness in minutes. Increase in stiffness duration from baseline represented disease progression and/or joint worsening, no change represented halting of disease progression, and a decrease represented improvement.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Health Assessment Questionnaire (HAQ) at Month 6</title>
        <description>HAQ: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire (HAQ) at Month 6</title>
          <description>HAQ: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Health Assessment Questionnaire (HAQ) at Month 12</title>
        <description>HAQ: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
        <time_frame>Month 12</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire (HAQ) at Month 12</title>
          <description>HAQ: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="139"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recent-Onset Arthritis Disability (ROAD) at Month 6</title>
        <description>ROAD questionnaire: valid and responsive tool for measuring functional ability in RA participants. Consists of 12-items related to fine movements of upper extremity, locomotor activities of lower extremity, and activities that involve both upper and lower extremities. For each item participant rated the level of difficulty over the past week on a 5-point scale ranging from 0 (without any difficulty) to 4 (unable to do). Total ROAD score were transformed to a 0 to 10 point scale, where 0 = best status and 10 = poorest status.</description>
        <time_frame>Month 6</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Recent-Onset Arthritis Disability (ROAD) at Month 6</title>
          <description>ROAD questionnaire: valid and responsive tool for measuring functional ability in RA participants. Consists of 12-items related to fine movements of upper extremity, locomotor activities of lower extremity, and activities that involve both upper and lower extremities. For each item participant rated the level of difficulty over the past week on a 5-point scale ranging from 0 (without any difficulty) to 4 (unable to do). Total ROAD score were transformed to a 0 to 10 point scale, where 0 = best status and 10 = poorest status.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.28" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Recent-Onset Arthritis Disability (ROAD) at Month 12</title>
        <description>ROAD questionnaire: valid and responsive tool for measuring functional ability in RA participants. Consists of 12-items related to fine movements of upper extremity, locomotor activities of lower extremity, and activities that involve both upper and lower extremities. For each item participant rated the level of difficulty over the past week on a 5-point scale ranging from 0 (without any difficulty) to 4 (unable to do). Total ROAD score were transformed to a 0 to 10 point scale, where 0 = best status and 10 = poorest status.</description>
        <time_frame>Month 12</time_frame>
        <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Recent-Onset Arthritis Disability (ROAD) at Month 12</title>
          <description>ROAD questionnaire: valid and responsive tool for measuring functional ability in RA participants. Consists of 12-items related to fine movements of upper extremity, locomotor activities of lower extremity, and activities that involve both upper and lower extremities. For each item participant rated the level of difficulty over the past week on a 5-point scale ranging from 0 (without any difficulty) to 4 (unable to do). Total ROAD score were transformed to a 0 to 10 point scale, where 0 = best status and 10 = poorest status.</description>
          <population>Analysis population included all participants who were enrolled in the study. Here &quot;N&quot; (number of participants analyzed) signifies participants who were evaluable for this measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="138"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.97" spread="1.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Radiological Assessment of Hands and Feet Based on Sharp-van Der Hejde (SvH) Scoring Method at Month 6</title>
        <description>SvH method included 16 areas for erosions and 15 areas for joint space narrowing (JSN) and subluxation/luxation in each hand, 6 areas for erosions and 6 areas for JSN and subluxation/luxation in each foot. Erosion per joint scored on 0-5 point scale; 0=normal joint to 5=complete collapse. Total erosion score for hands:0-160, for feet:0-120. JSN and subluxation/luxation scored on 0-4 point scale; 0=normal joint to 4= a bony ankylosis/a complete luxation of joint. Total JSN and subluxation/luxation score for hands:0-120, for feet:0-48. Total SvH score = 0-448; higher score=more erosion and JSN.</description>
        <time_frame>Month 6</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiological Assessment of Hands and Feet Based on Sharp-van Der Hejde (SvH) Scoring Method at Month 6</title>
          <description>SvH method included 16 areas for erosions and 15 areas for joint space narrowing (JSN) and subluxation/luxation in each hand, 6 areas for erosions and 6 areas for JSN and subluxation/luxation in each foot. Erosion per joint scored on 0-5 point scale; 0=normal joint to 5=complete collapse. Total erosion score for hands:0-160, for feet:0-120. JSN and subluxation/luxation scored on 0-4 point scale; 0=normal joint to 4= a bony ankylosis/a complete luxation of joint. Total JSN and subluxation/luxation score for hands:0-120, for feet:0-48. Total SvH score = 0-448; higher score=more erosion and JSN.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Radiological Assessment of Hands and Feet Based on Sharp-Van Der Hejde (SvH) Scoring Method at Month 12</title>
        <description>SvH method included 16 areas for erosions and 15 areas for JSN and subluxation/luxation in each hand, 6 areas for erosions and 6 areas for JSN and subluxation/luxation in each foot. Erosion per joint scored on 0-5 point scale; 0=normal joint to 5=complete collapse. Total erosion score for hands:0-160, for feet:0-120. JSN and subluxation/luxation scored on 0-4 point scale; 0=normal joint to 4= a bony ankylosis/a complete luxation of joint. Total JSN and subluxation/luxation score for hands:0-120, for feet:0-48. Total SvH score = 0-448; higher score=more erosion and JSN.</description>
        <time_frame>Month 12</time_frame>
        <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
        <group_list>
          <group group_id="O1">
            <title>All Participants</title>
            <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
          </group>
        </group_list>
        <measure>
          <title>Radiological Assessment of Hands and Feet Based on Sharp-Van Der Hejde (SvH) Scoring Method at Month 12</title>
          <description>SvH method included 16 areas for erosions and 15 areas for JSN and subluxation/luxation in each hand, 6 areas for erosions and 6 areas for JSN and subluxation/luxation in each foot. Erosion per joint scored on 0-5 point scale; 0=normal joint to 5=complete collapse. Total erosion score for hands:0-160, for feet:0-120. JSN and subluxation/luxation scored on 0-4 point scale; 0=normal joint to 4= a bony ankylosis/a complete luxation of joint. Total JSN and subluxation/luxation score for hands:0-120, for feet:0-48. Total SvH score = 0-448; higher score=more erosion and JSN.</description>
          <population>Data was not analyzed as per planned analysis because it was not considered significant to assess the outcome according to clinical opinion.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>All Participants</title>
          <description>Active Rheumatoid Arthritis (RA) participants who were partial or non-responders to the previous Disease Modifying Anti Rheumatic Drugs (DMARDs) treatment were prescribed with anti-Tumor Necrosis Factor (TNF) therapy (infliximab, etanercept, and adalimumab) as per usual clinical practice and observed for 12 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>No Coding Applied</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hospitalization for dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Local aedematous reaction, hard and pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Suspect of feocromocitoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Not Available</sub_title>
                <description>Information was collected from phone log data and no information was available about serious event occurred.</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>No Coding Applied</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Skin rash on abdomen and chest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Foot finger infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Visus disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Erythematous reaction in the injection site</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Vasculite episode</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Defluvium Capillorum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
              <event>
                <sub_title>Cystitis with fever</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

